Details
Implantable Technologies
Peptides and Small Molecules Drug DeliveryISSN 1. Aufl.
|
209,99 € |
|
| Verlag: | Royal Society Of Chemistry |
| Format: | EPUB |
| Veröffentl.: | 20.10.2021 |
| ISBN/EAN: | 9781839165368 |
| Sprache: | englisch |
| Anzahl Seiten: | 302 |
DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.
Beschreibungen
Implantable technologies allow for a sustained control over the release of pharmaceuticals into the bloodstream thereby achieving a controlled concentration with the potential to minimise side-effects while increasing patient compliance. Significant progress has been made in various alternative implantable delivery technologies, notably in intraocular and subcutaneous devices. Despite success in research and clinical studies, long-term clinical efficacy may be more limited and different aspects related to drug development and commercialization using these technologies are not well understood or practiced in the commercial setting. This book provides a comprehensive and cohesive picture of the latest in the field while also outlining the opportunities and challenges in implantable technology. Implantable Technologies: Pepties and Biologic Drug Development is an ideal reference for any postgraduate or researcher interested in utilising implantable technologies and novel routes of drug administration. The book will also be of interest to those involved in formulation and clinical application for a wide array of disease areas in addition to more established paradigms such as diabetes and pain management.
Implantable Technologies: Pepties and Biologic Drug Development is an ideal reference for any postgraduate or researcher interested in utilising implantable technologies and novel routes of drug administration.
Status of Implantable and Long-acting Injectable Technologies; Developing Complex Dosage Forms of Long- acting Biologics for the Eye: Current State, Challenges, and Opportunities; Monolithic Devices for Sustained Delivery of Protein Therapeutics for Ocular Disease; Sustained Delivery of Ocular Protein Therapeutics; Development of Risperidone Implant Formulations (DLP-114) for Long-term Maintenance Treatment of Schizophrenia; In-line Extrusion Process and Product Evaluation of ProNeura® by Near-infrared Spectroscopy; Addressing Immunogenicity for Implantable Drug-delivery Devices and Long-acting Injectables, Including Pharmacokinetic and Pharmacodynamic Correlations; Characterization Methods for Parenteral Peptide Controlled Release Drug Delivery Systems; Parenteral Delivery of Therapeutic Proteins, Peptides and Small Molecules Using Biodegradable Silica; Development of User-initiated Vaginal Dosage Forms; Three-dimensional Printed Implantable Products;
Diese Produkte könnten Sie auch interessieren:
